FCGRT and chronic inflammatory demyelinating polyradiculoneuropathy: FcRn blockers have begun to show promising results for patients with CIDP, with a recent FDA and EMA approval [13, 14] and another anti‐FcRn monoclonal antibody currently being evaluated in a phase 3 clinical trial [43].